New drug may lower blood clot risk following surgery, study findshttps://www.upi.com/Health_News/2021/07/19/abelacimab-blood-clots-study/5761626708650/July 19 (UPI) -- The drug abelacimab prevents blood clots in patients undergoing knee replacement surgery, a study published by the New England Journal of Medicine found.
Abelacimab, developed by Cambridge, Mass.-based Anthos Therapeutics, reduced the risk for blood clots in people who had the procedure by about 80% compared with the blood-thinner enoxaparin, the data showed.
The drug's effects appear to last for up to a month following surgery, the researchers said.
The discovery could offer people with or at risk for blood clots, including some victims of strokes, a potentially game-changing treatment, they said.
Judging by the number of participants in the study, ~400, this was a Phase 2 or 3 study. Thus the mab may be up to a year or 2 away from approval. As the UPI article points out, this mab could be useful in multiple medical contexts.
